Quantcast

Latest Biosimilar Stories

2014-03-18 23:01:55

The 26th annual EuroMeeting, coming to Austria’s capital from 25-27 March, will feature more than 100 sessions in 16 parallel themes and the chance to hear from 300+ expert speakers, including representatives from the European Medicines Agency (EMA), the European Commission and regulatory agencies from around the world. BASEL, SWITZERLAND (PRWEB) March 18, 2014 In less than one week’s time more than 2,500 professionals from around the world will gather in Vienna at DIA’s largest...

2014-03-14 04:20:45

REYKJAVIK, Iceland, March 14, 2014 /PRNewswire/ -- Alvotech, a powerful new player in the field of biopharmaceuticals and Finesse Solutions, Inc. ("Finesse"), today announce that they have entered into a partnership that will provide Alvotech with world-class, scalable, flexible and cost-efficient manufacturing and laboratory technology through the Finesse turnkey SmartFactory® GMP manufacturing platform suite. SmartFactory® is a single-use cGMP bio-manufacturing capacity, which...

2014-03-13 16:27:50

DUBLIN, Ireland, March 13, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/34kmnx/global_biosimilar) has announced the addition of the "Global Biosimilar Market Outlook 2018" [http://www.researchandmarkets.com/research/34kmnx/global_biosimilar ] report to their offering. <start_newscom> (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The global biosimilars market is at a crucial turning point, as...

2014-03-13 08:29:59

MUNICH, March 13, 2014 /PRNewswire/ -- Formycon AG has expanded its Advisory Board. With Dr. Bernhard Hampl, a top pharmaceuticals manager from the US has been acquired for the advisory body. Over the past 20 years, Dr. Bernhard Hampl was a successful CEO in large American generics companies such as EON LABS Inc. and later Sandoz US, which after fusion of the two companies became America's second-largest manufacturer of generics. Dr. Hampl, who started his...

2014-03-12 20:24:16

DUBLIN, March 12, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that the United States District Court for the Eastern District of Virginia has ruled that United States Patent No. RE44,048 (the '048 Patent) is invalid. Actavis was earlier sued by Plaintiffs G.D. Searle LLC and Pfizer Asia Pacific PTE, Ltd. for infringement of the '048 Patent in connection with its Abbreviated New Drug Application directed to Actavis' generic version of Pfizer's Celebrex® (celecoxib)...

2014-03-12 08:29:55

MUNICH, March 12, 2014 /PRNewswire/ -- - The long-term orientation of Formycon AG as a global biosimilar developer has been successfully achieved. The company ended the year 2013 with the out-licensing of the first development project. - With Carsten Brockmeyer, Gerhard Schaefer and Simon Sturge, Formycon has appointed experienced pharma managers to the board of directors and the advisory board. -...

2014-02-28 16:23:59

DUBLIN, Feb. 28, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Colchicine Tablets USP, 0.6 mg. Actavis' ANDA product is a generic version of Takeda's Colcrys(®), which is a prescription medicine used in adults to prevent and treat gout flares. Takeda Pharmaceuticals U.S.A., Inc. filed suit against Actavis on February 27, 2014 in the...

2014-02-28 08:25:23

DUBLIN, Feb. 28, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Dronedarone Hydrochloride Tablets 400 mg. Actavis' ANDA product is a generic version of Sanofi's Multaq(®), which is an antiarrhythmic drug indicated to reduce the risk of hospitalization for atrial fibrillation (AF) in patients in sinus rhythm with a history of...

2014-02-27 12:27:03

CHICAGO, Feb. 27, 2014 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Dr. Reddy's Laboratories Ltd. (NYSE:RDY-Free Report), Actavis plc (NYSE:ACT-Free Report), Amgen Inc. (Nasdaq:AMGN-Free Report), Biogen Idec Inc. (Nasdaq:BIIB-Free Report) and eBay Inc. (Nasdaq:EBAY-Free...

2014-02-26 20:22:18

DUBLIN, February 26, 2014 /PRNewswire/ -- Dublin - Research and Markets ( http://www.researchandmarkets.com/research/h27svw/flatrate) has announced the addition of the "Flat-Rate Subscription to In-Depth Publishing Reports on Oncology, Biosimilars, Antibodies, Proteins and Vaccines" [http://www.researchandmarkets.com/research/h27svw/flatrate ] subscription to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Subscription to this product...


Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related